S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ALZN Alzamend Neuro Inc

1.42

-0.04 (-2.74%)

Nov 15 2024 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Alzamend Neuro Charts.

Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Alzamend Neuro Charts.

Alzamend Neuro Inc News

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Wednesday 16 October 2024 (1 month ago) • Business Wire

Form 8-K - Current report
Tuesday 15 October 2024 (1 month ago) • Edgar (US Regulatory)

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Tuesday 15 October 2024 (1 month ago) • Business Wire

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
Thursday 10 October 2024 (1 month ago) • Business Wire

Form 424B5 - Prospectus [Rule 424(b)(5)]
Thursday 3 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 3 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 11 September 2024 (2 months ago) • Edgar (US Regulatory)

Alzamend Neuro Issues Letter to Stockholders
Monday 26 August 2024 (3 months ago) • Business Wire

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
Monday 19 August 2024 (3 months ago) • Business Wire

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
Monday 12 August 2024 (3 months ago) • Business Wire

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
Tuesday 6 August 2024 (3 months ago) • Business Wire

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
Monday 5 August 2024 (3 months ago) • Business Wire

More Alzamend Neuro Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions